nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinolone Acetonide—PLA2G4A—Raltitrexed—Methotrexate—colon cancer	0.0453	1	CbGdCrCtD
Fluocinolone Acetonide—Ear discomfort—Capecitabine—colon cancer	0.0338	0.0456	CcSEcCtD
Fluocinolone Acetonide—Telangiectasia—Fluorouracil—colon cancer	0.0337	0.0454	CcSEcCtD
Fluocinolone Acetonide—Common cold—Fluorouracil—colon cancer	0.0305	0.041	CcSEcCtD
Fluocinolone Acetonide—Allergic contact dermatitis—Fluorouracil—colon cancer	0.0227	0.0306	CcSEcCtD
Fluocinolone Acetonide—Skin irritation—Fluorouracil—colon cancer	0.0184	0.0248	CcSEcCtD
Fluocinolone Acetonide—Telangiectasia—Methotrexate—colon cancer	0.0175	0.0236	CcSEcCtD
Fluocinolone Acetonide—Lacrimation—Irinotecan—colon cancer	0.0141	0.019	CcSEcCtD
Fluocinolone Acetonide—Lacrimation—Fluorouracil—colon cancer	0.0135	0.0182	CcSEcCtD
Fluocinolone Acetonide—Skin hyperpigmentation—Fluorouracil—colon cancer	0.0134	0.018	CcSEcCtD
Fluocinolone Acetonide—Taste metallic—Methotrexate—colon cancer	0.013	0.0175	CcSEcCtD
Fluocinolone Acetonide—Blepharitis—Fluorouracil—colon cancer	0.0129	0.0174	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of Androgen receptor activity—SPDEF—colon cancer	0.0102	0.103	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—smooth muscle tissue—colon cancer	0.01	0.103	CbGeAlD
Fluocinolone Acetonide—Leukoderma—Methotrexate—colon cancer	0.00973	0.0131	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—renal system—colon cancer	0.00965	0.0988	CbGeAlD
Fluocinolone Acetonide—SERPINA6—renal system—colon cancer	0.00961	0.0984	CbGeAlD
Fluocinolone Acetonide—Impaired healing—Methotrexate—colon cancer	0.00956	0.0129	CcSEcCtD
Fluocinolone Acetonide—Visual acuity reduced—Capecitabine—colon cancer	0.00934	0.0126	CcSEcCtD
Fluocinolone Acetonide—Skin hyperpigmentation—Capecitabine—colon cancer	0.00934	0.0126	CcSEcCtD
Fluocinolone Acetonide—Eye irritation—Fluorouracil—colon cancer	0.00931	0.0125	CcSEcCtD
Fluocinolone Acetonide—Lacrimation increased—Irinotecan—colon cancer	0.009	0.0121	CcSEcCtD
Fluocinolone Acetonide—Herpes simplex—Fluorouracil—colon cancer	0.00862	0.0116	CcSEcCtD
Fluocinolone Acetonide—Lacrimation increased—Fluorouracil—colon cancer	0.00862	0.0116	CcSEcCtD
Fluocinolone Acetonide—Dermatitis contact—Fluorouracil—colon cancer	0.00785	0.0106	CcSEcCtD
Fluocinolone Acetonide—Photophobia—Fluorouracil—colon cancer	0.00746	0.0101	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—bone marrow—colon cancer	0.0073	0.0747	CbGeAlD
Fluocinolone Acetonide—SERPINA6—bone marrow—colon cancer	0.00727	0.0744	CbGeAlD
Fluocinolone Acetonide—Otitis media—Capecitabine—colon cancer	0.00713	0.00961	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—vagina—colon cancer	0.00699	0.0716	CbGeAlD
Fluocinolone Acetonide—Skin hyperpigmentation—Methotrexate—colon cancer	0.00695	0.00936	CcSEcCtD
Fluocinolone Acetonide—Rhinorrhoea—Capecitabine—colon cancer	0.00686	0.00923	CcSEcCtD
Fluocinolone Acetonide—Folliculitis—Methotrexate—colon cancer	0.00658	0.00886	CcSEcCtD
Fluocinolone Acetonide—Eye irritation—Capecitabine—colon cancer	0.0065	0.00876	CcSEcCtD
Fluocinolone Acetonide—Visual disturbance—Irinotecan—colon cancer	0.00636	0.00856	CcSEcCtD
Fluocinolone Acetonide—Pain in extremity—Vincristine—colon cancer	0.00619	0.00833	CcSEcCtD
Fluocinolone Acetonide—Herpes simplex—Capecitabine—colon cancer	0.00603	0.00812	CcSEcCtD
Fluocinolone Acetonide—Lacrimation increased—Capecitabine—colon cancer	0.00603	0.00812	CcSEcCtD
Fluocinolone Acetonide—SERPINA6—liver—colon cancer	0.00587	0.0601	CbGeAlD
Fluocinolone Acetonide—Cataract—Capecitabine—colon cancer	0.00583	0.00786	CcSEcCtD
Fluocinolone Acetonide—Neck pain—Capecitabine—colon cancer	0.00562	0.00757	CcSEcCtD
Fluocinolone Acetonide—NR3C1—embryo—colon cancer	0.00556	0.0569	CbGeAlD
Fluocinolone Acetonide—Abscess—Methotrexate—colon cancer	0.00523	0.00704	CcSEcCtD
Fluocinolone Acetonide—Nasopharyngitis—Fluorouracil—colon cancer	0.00516	0.00695	CcSEcCtD
Fluocinolone Acetonide—Dry eye—Capecitabine—colon cancer	0.00513	0.00691	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Irinotecan—colon cancer	0.00484	0.00652	CcSEcCtD
Fluocinolone Acetonide—Ear pain—Capecitabine—colon cancer	0.00473	0.00636	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Fluorouracil—colon cancer	0.00463	0.00624	CcSEcCtD
Fluocinolone Acetonide—Gastroenteritis—Capecitabine—colon cancer	0.00455	0.00613	CcSEcCtD
Fluocinolone Acetonide—NR3C1—epithelium—colon cancer	0.00454	0.0465	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—lymph node—colon cancer	0.00452	0.0463	CbGeAlD
Fluocinolone Acetonide—Herpes simplex—Methotrexate—colon cancer	0.00449	0.00604	CcSEcCtD
Fluocinolone Acetonide—Eye pain—Capecitabine—colon cancer	0.00447	0.00602	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Fluorouracil—colon cancer	0.00445	0.00599	CcSEcCtD
Fluocinolone Acetonide—Infestation—Fluorouracil—colon cancer	0.00445	0.00599	CcSEcCtD
Fluocinolone Acetonide—NR3C1—smooth muscle tissue—colon cancer	0.00437	0.0448	CbGeAlD
Fluocinolone Acetonide—NR3C1—renal system—colon cancer	0.00421	0.0431	CbGeAlD
Fluocinolone Acetonide—Connective tissue disorder—Vincristine—colon cancer	0.0042	0.00566	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Irinotecan—colon cancer	0.00418	0.00563	CcSEcCtD
Fluocinolone Acetonide—Sinusitis—Fluorouracil—colon cancer	0.00417	0.00562	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Irinotecan—colon cancer	0.0041	0.00552	CcSEcCtD
Fluocinolone Acetonide—Pain in extremity—Capecitabine—colon cancer	0.00403	0.00543	CcSEcCtD
Fluocinolone Acetonide—Diplopia—Capecitabine—colon cancer	0.00403	0.00543	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Irinotecan—colon cancer	0.00402	0.00541	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Fluorouracil—colon cancer	0.004	0.00539	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—PTPRJ—colon cancer	0.00398	0.04	CbGpPWpGaD
Fluocinolone Acetonide—Mediastinal disorder—Vincristine—colon cancer	0.00386	0.00519	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Vincristine—colon cancer	0.00378	0.00509	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Irinotecan—colon cancer	0.00376	0.00506	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Vincristine—colon cancer	0.00375	0.00505	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Irinotecan—colon cancer	0.00368	0.00496	CcSEcCtD
Fluocinolone Acetonide—Nasopharyngitis—Capecitabine—colon cancer	0.00361	0.00486	CcSEcCtD
Fluocinolone Acetonide—Back pain—Vincristine—colon cancer	0.0036	0.00485	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Fluorouracil—colon cancer	0.00353	0.00475	CcSEcCtD
Fluocinolone Acetonide—Back pain—Irinotecan—colon cancer	0.00351	0.00473	CcSEcCtD
Fluocinolone Acetonide—NR3C1—lymphoid tissue—colon cancer	0.0035	0.0358	CbGeAlD
Fluocinolone Acetonide—Influenza—Capecitabine—colon cancer	0.00348	0.00469	CcSEcCtD
Fluocinolone Acetonide—Erythema—Fluorouracil—colon cancer	0.00347	0.00468	CcSEcCtD
Fluocinolone Acetonide—NR3C1—digestive system—colon cancer	0.00345	0.0354	CbGeAlD
Fluocinolone Acetonide—NR3C1—Nuclear Receptors—HNF4A—colon cancer	0.00342	0.0343	CbGpPWpGaD
Fluocinolone Acetonide—Vertigo—Vincristine—colon cancer	0.00335	0.00451	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Fluorouracil—colon cancer	0.00327	0.00441	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Irinotecan—colon cancer	0.00326	0.00439	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Capecitabine—colon cancer	0.00324	0.00436	CcSEcCtD
Fluocinolone Acetonide—NR3C1—bone marrow—colon cancer	0.00318	0.0326	CbGeAlD
Fluocinolone Acetonide—Visual disturbance—Methotrexate—colon cancer	0.00317	0.00427	CcSEcCtD
Fluocinolone Acetonide—Cough—Irinotecan—colon cancer	0.00317	0.00426	CcSEcCtD
Fluocinolone Acetonide—Infestation—Capecitabine—colon cancer	0.00311	0.00418	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Capecitabine—colon cancer	0.00311	0.00418	CcSEcCtD
Fluocinolone Acetonide—NR3C1—vagina—colon cancer	0.00305	0.0312	CbGeAlD
Fluocinolone Acetonide—Oedema—Vincristine—colon cancer	0.00304	0.00409	CcSEcCtD
Fluocinolone Acetonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—HNF4A—colon cancer	0.00304	0.0305	CbGpPWpGaD
Fluocinolone Acetonide—Infection—Vincristine—colon cancer	0.00302	0.00407	CcSEcCtD
Fluocinolone Acetonide—Fluticasone furoate—ABCB1—colon cancer	0.00298	0.198	CrCbGaD
Fluocinolone Acetonide—Nervous system disorder—Vincristine—colon cancer	0.00298	0.00402	CcSEcCtD
Fluocinolone Acetonide—Oedema—Irinotecan—colon cancer	0.00296	0.00399	CcSEcCtD
Fluocinolone Acetonide—Infection—Irinotecan—colon cancer	0.00294	0.00396	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Irinotecan—colon cancer	0.0029	0.00391	CcSEcCtD
Fluocinolone Acetonide—Oedema—Fluorouracil—colon cancer	0.00284	0.00382	CcSEcCtD
Fluocinolone Acetonide—Infection—Fluorouracil—colon cancer	0.00282	0.00379	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Capecitabine—colon cancer	0.0028	0.00377	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Fluorouracil—colon cancer	0.00278	0.00375	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Vincristine—colon cancer	0.00277	0.00373	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Capecitabine—colon cancer	0.00274	0.00369	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptor transcription pathway—HNF4A—colon cancer	0.0027	0.0271	CbGpPWpGaD
Fluocinolone Acetonide—Visual impairment—Capecitabine—colon cancer	0.00269	0.00362	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Vincristine—colon cancer	0.00262	0.00354	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Capecitabine—colon cancer	0.00261	0.00351	CcSEcCtD
Fluocinolone Acetonide—Pain—Vincristine—colon cancer	0.0026	0.0035	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00258	0.00348	CcSEcCtD
Fluocinolone Acetonide—NR3C1—liver—colon cancer	0.00257	0.0263	CbGeAlD
Fluocinolone Acetonide—Gastrointestinal disorder—Irinotecan—colon cancer	0.00256	0.00344	CcSEcCtD
Fluocinolone Acetonide—Pain—Irinotecan—colon cancer	0.00253	0.00341	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—colon cancer	0.00251	0.0253	CbGpPWpGaD
Fluocinolone Acetonide—Mediastinal disorder—Capecitabine—colon cancer	0.00251	0.00339	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Capecitabine—colon cancer	0.00246	0.00332	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00245	0.0033	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Capecitabine—colon cancer	0.00244	0.00329	CcSEcCtD
Fluocinolone Acetonide—Erythema—Capecitabine—colon cancer	0.00243	0.00327	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Capecitabine—colon cancer	0.00243	0.00327	CcSEcCtD
Fluocinolone Acetonide—Pain—Fluorouracil—colon cancer	0.00242	0.00327	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Methotrexate—colon cancer	0.00241	0.00325	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Vincristine—colon cancer	0.0024	0.00324	CcSEcCtD
Fluocinolone Acetonide—Methylprednisolone—ABCB1—colon cancer	0.00238	0.158	CrCbGaD
Fluocinolone Acetonide—Dysgeusia—Capecitabine—colon cancer	0.00238	0.0032	CcSEcCtD
Fluocinolone Acetonide—Triamcinolone—PTGS2—colon cancer	0.00236	0.157	CrCbGaD
Fluocinolone Acetonide—Back pain—Capecitabine—colon cancer	0.00235	0.00316	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Irinotecan—colon cancer	0.00234	0.00315	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Methotrexate—colon cancer	0.00231	0.00312	CcSEcCtD
Fluocinolone Acetonide—Infestation—Methotrexate—colon cancer	0.00231	0.00312	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	0.00231	0.0232	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Transcription factor regulation in adipogenesis—PPARG—colon cancer	0.0023	0.0231	CbGpPWpGaD
Fluocinolone Acetonide—Vision blurred—Capecitabine—colon cancer	0.00229	0.00308	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Fluorouracil—colon cancer	0.00224	0.00302	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Vincristine—colon cancer	0.00224	0.00302	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Capecitabine—colon cancer	0.00218	0.00294	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Irinotecan—colon cancer	0.00218	0.00294	CcSEcCtD
Fluocinolone Acetonide—Cough—Capecitabine—colon cancer	0.00212	0.00285	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Fluorouracil—colon cancer	0.00209	0.00281	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Vincristine—colon cancer	0.00208	0.0028	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Capecitabine—colon cancer	0.00207	0.00278	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Irinotecan—colon cancer	0.00203	0.00273	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Vincristine—colon cancer	0.00201	0.00271	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Fluorouracil—colon cancer	0.00201	0.0027	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Methotrexate—colon cancer	0.002	0.00269	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGS2—colon cancer	0.00199	0.02	CbGpPWpGaD
Fluocinolone Acetonide—Oedema—Capecitabine—colon cancer	0.00198	0.00267	CcSEcCtD
Fluocinolone Acetonide—NR3C1—lymph node—colon cancer	0.00197	0.0202	CbGeAlD
Fluocinolone Acetonide—Infection—Capecitabine—colon cancer	0.00197	0.00265	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Irinotecan—colon cancer	0.00196	0.00264	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Capecitabine—colon cancer	0.00194	0.00262	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Methotrexate—colon cancer	0.00194	0.00261	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Fluorouracil—colon cancer	0.00194	0.00261	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Vincristine—colon cancer	0.00193	0.0026	CcSEcCtD
Fluocinolone Acetonide—Betamethasone—PTGS2—colon cancer	0.00193	0.128	CrCbGaD
Fluocinolone Acetonide—Rash—Vincristine—colon cancer	0.00192	0.00258	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Vincristine—colon cancer	0.00192	0.00258	CcSEcCtD
Fluocinolone Acetonide—Headache—Vincristine—colon cancer	0.0019	0.00257	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Irinotecan—colon cancer	0.00188	0.00254	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Fluorouracil—colon cancer	0.00188	0.00253	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Methotrexate—colon cancer	0.00187	0.00252	CcSEcCtD
Fluocinolone Acetonide—Rash—Irinotecan—colon cancer	0.00187	0.00251	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Irinotecan—colon cancer	0.00187	0.00251	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—HNF4A—colon cancer	0.00186	0.0187	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—ADP signalling through P2Y purinoceptor 1—SRC—colon cancer	0.00186	0.0187	CbGpPWpGaD
Fluocinolone Acetonide—Headache—Irinotecan—colon cancer	0.00185	0.0025	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Methotrexate—colon cancer	0.00183	0.00247	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Methotrexate—colon cancer	0.00182	0.00245	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Methotrexate—colon cancer	0.00181	0.00243	CcSEcCtD
Fluocinolone Acetonide—Erythema—Methotrexate—colon cancer	0.00181	0.00243	CcSEcCtD
Fluocinolone Acetonide—Nausea—Vincristine—colon cancer	0.00181	0.00243	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00181	0.00243	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Fluorouracil—colon cancer	0.0018	0.00243	CcSEcCtD
Fluocinolone Acetonide—Rash—Fluorouracil—colon cancer	0.00179	0.00241	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Fluorouracil—colon cancer	0.00179	0.00241	CcSEcCtD
Fluocinolone Acetonide—Headache—Fluorouracil—colon cancer	0.00178	0.00239	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Methotrexate—colon cancer	0.00177	0.00238	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—PTGS2—colon cancer	0.00176	0.0177	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Irinotecan—colon cancer	0.00176	0.00237	CcSEcCtD
Fluocinolone Acetonide—Back pain—Methotrexate—colon cancer	0.00175	0.00235	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Capecitabine—colon cancer	0.00171	0.0023	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Methotrexate—colon cancer	0.0017	0.00229	CcSEcCtD
Fluocinolone Acetonide—Pain—Capecitabine—colon cancer	0.00169	0.00228	CcSEcCtD
Fluocinolone Acetonide—Nausea—Fluorouracil—colon cancer	0.00168	0.00227	CcSEcCtD
Fluocinolone Acetonide—Prednisolone—ABCB1—colon cancer	0.00168	0.111	CrCbGaD
Fluocinolone Acetonide—Betamethasone—ABCB1—colon cancer	0.00164	0.109	CrCbGaD
Fluocinolone Acetonide—Vertigo—Methotrexate—colon cancer	0.00162	0.00219	CcSEcCtD
Fluocinolone Acetonide—Cough—Methotrexate—colon cancer	0.00158	0.00212	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	0.00158	0.0158	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signal amplification—SRC—colon cancer	0.00157	0.0158	CbGpPWpGaD
Fluocinolone Acetonide—Body temperature increased—Capecitabine—colon cancer	0.00157	0.00211	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Methotrexate—colon cancer	0.00154	0.00207	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptors—PPARG—colon cancer	0.00148	0.0149	CbGpPWpGaD
Fluocinolone Acetonide—Infection—Methotrexate—colon cancer	0.00147	0.00197	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Capecitabine—colon cancer	0.00146	0.00197	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Methotrexate—colon cancer	0.00145	0.00195	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Capecitabine—colon cancer	0.0014	0.00189	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Capecitabine—colon cancer	0.00136	0.00183	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Methotrexate—colon cancer	0.00134	0.00181	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	0.00133	0.0133	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Arachidonic acid metabolism—PTGS2—colon cancer	0.00132	0.0133	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Capecitabine—colon cancer	0.00131	0.00176	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—p38 MAPK Signaling Pathway—MYC—colon cancer	0.00131	0.0131	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGF Pathway—SRC—colon cancer	0.00131	0.0131	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Methotrexate—colon cancer	0.00127	0.00172	CcSEcCtD
Fluocinolone Acetonide—Pain—Methotrexate—colon cancer	0.00126	0.0017	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Capecitabine—colon cancer	0.00126	0.0017	CcSEcCtD
Fluocinolone Acetonide—Rash—Capecitabine—colon cancer	0.00125	0.00168	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Capecitabine—colon cancer	0.00125	0.00168	CcSEcCtD
Fluocinolone Acetonide—Headache—Capecitabine—colon cancer	0.00124	0.00167	CcSEcCtD
Fluocinolone Acetonide—Nausea—Capecitabine—colon cancer	0.00118	0.00159	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptor transcription pathway—PPARG—colon cancer	0.00117	0.0118	CbGpPWpGaD
Fluocinolone Acetonide—Body temperature increased—Methotrexate—colon cancer	0.00117	0.00157	CcSEcCtD
Fluocinolone Acetonide—Dexamethasone—PTGS2—colon cancer	0.00112	0.0747	CrCbGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—BAX—colon cancer	0.00109	0.011	CbGpPWpGaD
Fluocinolone Acetonide—Hypersensitivity—Methotrexate—colon cancer	0.00109	0.00146	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.00106	0.0107	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—colon cancer	0.00105	0.0105	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Methotrexate—colon cancer	0.00104	0.00141	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—p38 MAPK Signaling Pathway—HRAS—colon cancer	0.00103	0.0103	CbGpPWpGaD
Fluocinolone Acetonide—Diarrhoea—Methotrexate—colon cancer	0.00101	0.00136	CcSEcCtD
Fluocinolone Acetonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—colon cancer	0.000991	0.00996	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—CASP3—colon cancer	0.000984	0.00989	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Methotrexate—colon cancer	0.000975	0.00131	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—APC—colon cancer	0.000965	0.0097	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CA7—colon cancer	0.000961	0.00966	CbGpPWpGaD
Fluocinolone Acetonide—Dexamethasone—ABCB1—colon cancer	0.000956	0.0635	CrCbGaD
Fluocinolone Acetonide—Vomiting—Methotrexate—colon cancer	0.000938	0.00126	CcSEcCtD
Fluocinolone Acetonide—Rash—Methotrexate—colon cancer	0.00093	0.00125	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Methotrexate—colon cancer	0.000929	0.00125	CcSEcCtD
Fluocinolone Acetonide—Headache—Methotrexate—colon cancer	0.000924	0.00124	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGF Pathway—HRAS—colon cancer	0.000919	0.00924	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Endothelins—SRC—colon cancer	0.00089	0.00894	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Methotrexate—colon cancer	0.000876	0.00118	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—SRC—colon cancer	0.000857	0.00862	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	0.000828	0.00832	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	0.000813	0.00817	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—BRAF—colon cancer	0.000787	0.00791	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	0.000783	0.00787	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—EGFR—colon cancer	0.000751	0.00755	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of Androgen receptor activity—EP300—colon cancer	0.000743	0.00747	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of Androgen receptor activity—SRC—colon cancer	0.000723	0.00727	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Circadian Clock—EP300—colon cancer	0.000722	0.00725	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—PIK3CA—colon cancer	0.000695	0.00698	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—CTNNB1—colon cancer	0.000655	0.00659	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CCND1—colon cancer	0.000647	0.0065	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—HRAS—colon cancer	0.000643	0.00646	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CTNNB1—colon cancer	0.00064	0.00644	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Endothelins—HRAS—colon cancer	0.000626	0.00629	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—APC—colon cancer	0.000597	0.006	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—EP300—colon cancer	0.000595	0.00598	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CHST5—colon cancer	0.000583	0.00586	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ODC1—colon cancer	0.000583	0.00586	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—AKT1—colon cancer	0.000567	0.0057	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—colon cancer	0.000557	0.00559	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—PPARG—colon cancer	0.000554	0.00557	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Endothelins—AKT1—colon cancer	0.000553	0.00556	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—colon cancer	0.000551	0.00554	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—AKT1—colon cancer	0.000533	0.00536	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—colon cancer	0.00053	0.00532	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—TGFB1—colon cancer	0.000529	0.00532	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—EP300—colon cancer	0.000524	0.00527	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—colon cancer	0.000521	0.00524	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—MYC—colon cancer	0.000519	0.00521	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—DLC1—colon cancer	0.000518	0.00521	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—TGFB1—colon cancer	0.000517	0.0052	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—SRC—colon cancer	0.000514	0.00517	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—NRAS—colon cancer	0.000495	0.00497	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—LGR5—colon cancer	0.000487	0.0049	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—HNF4A—colon cancer	0.000466	0.00469	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—colon cancer	0.000461	0.00464	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—MYC—colon cancer	0.000461	0.00463	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	0.000453	0.00455	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—TP53—colon cancer	0.000426	0.00428	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—KRAS—colon cancer	0.000426	0.00428	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	0.000421	0.00423	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	0.000409	0.00411	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	0.000405	0.00407	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	0.000396	0.00398	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—PIK3CA—colon cancer	0.000391	0.00393	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—CTNNB1—colon cancer	0.00039	0.00392	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—CDKN1A—colon cancer	0.000381	0.00383	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	0.000377	0.00379	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—colon cancer	0.000375	0.00377	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	0.000366	0.00368	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—HRAS—colon cancer	0.000362	0.00364	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—PIK3CA—colon cancer	0.000361	0.00363	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	0.000357	0.00359	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—AXIN2—colon cancer	0.00035	0.00352	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—CASP3—colon cancer	0.00035	0.00352	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—CTNNB1—colon cancer	0.000337	0.00339	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	0.000328	0.0033	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	0.000328	0.00329	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—SRC—colon cancer	0.000326	0.00328	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	0.000321	0.00323	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—colon cancer	0.00032	0.00322	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—colon cancer	0.000318	0.00319	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—AKT1—colon cancer	0.000317	0.00319	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—TGFB1—colon cancer	0.000315	0.00317	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—EP300—colon cancer	0.000313	0.00315	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	0.000303	0.00305	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—VEGFA—colon cancer	0.000297	0.00298	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—TGFB1—colon cancer	0.000291	0.00293	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	0.000279	0.0028	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	0.00027	0.00271	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	0.000248	0.00249	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PPARG—colon cancer	0.00024	0.00242	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	0.000228	0.00229	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—HNF4A—colon cancer	0.000224	0.00226	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—colon cancer	0.000203	0.00204	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—PPARG—colon cancer	0.000202	0.00203	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	0.000189	0.0019	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—EP300—colon cancer	0.000173	0.00174	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—SRC—colon cancer	0.000168	0.00169	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—VEGFA—colon cancer	0.000164	0.00165	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—NRAS—colon cancer	0.000162	0.00163	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—EP300—colon cancer	0.000157	0.00158	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ABCB1—colon cancer	0.000154	0.00155	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—TYMS—colon cancer	0.000151	0.00152	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—TGFB1—colon cancer	0.00015	0.00151	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—KRAS—colon cancer	0.000139	0.0014	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PIK3CA—colon cancer	0.000128	0.00129	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—TP53—colon cancer	0.000124	0.00124	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—HRAS—colon cancer	0.000118	0.00119	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	0.000116	0.00117	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—MYC—colon cancer	0.000115	0.00116	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PPARG—colon cancer	0.000107	0.00108	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—AKT1—colon cancer	0.000104	0.00105	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—FGFR3—colon cancer	0.000101	0.00102	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—PPARG—colon cancer	9.75e-05	0.00098	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—APC—colon cancer	9.28e-05	0.000933	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—NRAS—colon cancer	9.28e-05	0.000933	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—BRAF—colon cancer	8.72e-05	0.000877	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—EGFR—colon cancer	8.45e-05	0.00085	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PTGS2—colon cancer	8.42e-05	0.000847	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—KRAS—colon cancer	7.99e-05	0.000803	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PIK3CA—colon cancer	7.34e-05	0.000737	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—EP300—colon cancer	7.01e-05	0.000704	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—HRAS—colon cancer	6.79e-05	0.000682	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CASP3—colon cancer	6.54e-05	0.000657	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CCND1—colon cancer	6.37e-05	0.00064	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CTNNB1—colon cancer	6.3e-05	0.000634	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CDKN1A—colon cancer	6.16e-05	0.000619	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—AKT1—colon cancer	5.99e-05	0.000602	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—EP300—colon cancer	5.86e-05	0.000589	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—SRC—colon cancer	5.7e-05	0.000573	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—MYC—colon cancer	5.56e-05	0.000558	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—VEGFA—colon cancer	5.55e-05	0.000558	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—NRAS—colon cancer	5.48e-05	0.000551	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PIK3CA—colon cancer	5.18e-05	0.000521	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MYC—colon cancer	5.11e-05	0.000513	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TGFB1—colon cancer	5.09e-05	0.000512	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—EGFR—colon cancer	4.99e-05	0.000502	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—KRAS—colon cancer	4.72e-05	0.000474	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PIK3CA—colon cancer	4.33e-05	0.000436	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—AKT1—colon cancer	4.23e-05	0.000426	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TP53—colon cancer	4.19e-05	0.000421	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—HRAS—colon cancer	4.01e-05	0.000403	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—AKT1—colon cancer	3.85e-05	0.000387	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—AKT1—colon cancer	3.54e-05	0.000356	CbGpPWpGaD
